{"protocolSection": {"identificationModule": {"nctId": "NCT00308685", "orgStudyIdInfo": {"id": "IXR-303-25-167"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics", "officialTitle": "Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI (PROAIR\u2122 HFA (Albuterol Sulfate) Breath Actuated Inhalation Aerosol) in Pediatric Asthmatics"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2006-12-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2006-12-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-03-28", "studyFirstSubmitQcDate": "2006-03-28", "studyFirstPostDateStruct": {"date": "2006-03-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-01-31", "resultsFirstSubmitQcDate": "2022-01-31", "resultsFirstPostDateStruct": {"date": "2022-02-24", "type": "ACTUAL"}, "dispFirstSubmitDate": "2013-08-27", "dispFirstSubmitQcDate": "2013-08-27", "dispFirstPostDateStruct": {"date": "2013-09-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-03-22", "lastUpdatePostDateStruct": {"date": "2022-04-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma. The dosing period lasts three weeks and starts following a three-week run-in period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Pediatric asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 95, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Albuterol-HFA-BAI", "type": "EXPERIMENTAL", "description": "ProAir(TM) HFA, Breath Actuated Inhalation Aerosol", "interventionNames": ["Drug: Albuterol"]}, {"label": "Placebo-HFA-BAI", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Albuterol", "description": "Albuterol 90mcg", "armGroupLabels": ["Albuterol-HFA-BAI"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo", "armGroupLabels": ["Placebo-HFA-BAI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22", "description": "The baseline FEV1 was defined as the average of the two predose measurements ( at -0.5 and 0.0 hour) on the test day (Day 22). The mean was obtained from the analysis of covariance (ANCOVA) adjusted for baseline FEV1 and the pooled investigational center.", "timeFrame": "Baseline (Predose at Day 22), 2 hours postdose at Day 22"}], "secondaryOutcomes": [{"measure": "Baseline-Adjusted Area Under the Percent-Predicted FEV1 Versus Time Curve Over 6 Hours (PPFEV1 AUEC0-6) at Day 22", "description": "Baseline-adjusted PPFEV1 AUEC0-6 on Study Day 22 was determined using both the Day 1 and Day 22 baselines.", "timeFrame": "Predose (30 and 5 minutes) and 15, 30, 45, 60, 120, 240, and 360 minutes postdose at Day 22"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening\n* Male and female children aged 4-11 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 60-90%\n* Ability to perform spirometry\n* Demonstrate 12% airways reversibility\n\nExclusion Criteria:\n\n* Require continuous treatment with beta-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids\n* Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic diseases", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Medical Expert, M.D.", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Little Rock Allergy and Asthma", "city": "Little Rock", "state": "Arkansas", "zip": "72205-4565", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Allergy & Asthma Specialist Medical Group", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Allergy & Asthma Associates of Santa Clara Valley Research Center", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "William Storms Medical Research", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Colorado Allergy and Asthma Centers, PC", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Colorado Allergy and Asthma Centers, PC", "city": "Englewood", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "Colorado Allergy and Asthma Centers, PC", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Southern Allergy & Asthma, PC", "city": "Savannah", "state": "Georgia", "zip": "31405", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Sneeze, Wheeze & Itch Associates, Inc.", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Clinical Research Institute", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "The Asthma & Allergy Center, PC", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Allergy and Respiratory Center", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Allergy, Asthma & Clinical Research Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Pediatric Pulmonary Associates of North Texas", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Albuterol-HFA-BAI", "description": "Participants received albuterol"}, {"id": "FG001", "title": "Placebo-HFA-BAI", "description": "Participants received placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "47"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Need to administer prohibited medication", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Other than specified", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants", "groups": [{"id": "BG000", "title": "Albuterol-HFA-BAI", "description": "Participants received albuterol"}, {"id": "BG001", "title": "Placebo-HFA-BAI", "description": "Participants received placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "95"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "2.22"}, {"groupId": "BG001", "value": "8.8", "spread": "1.58"}, {"groupId": "BG002", "value": "8.5", "spread": "1.96"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "53"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "42"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Race", "categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "71"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "22"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Forced Expiratory Volume in 1 Second (FEV1)", "description": "The baseline FEV1 was defined as the average of the 2 test-day (Day 22) predose (-0.5 and 0.0 hour prior to dosing) baseline FEV1 values.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.52", "spread": "0.44"}, {"groupId": "BG001", "value": "1.61", "spread": "0.38"}, {"groupId": "BG002", "value": "1.56", "spread": "0.42"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Observed up to 2 Hours Following Completion of Dosing (FEV1max%0-2) at Day 22", "description": "The baseline FEV1 was defined as the average of the two predose measurements ( at -0.5 and 0.0 hour) on the test day (Day 22). The mean was obtained from the analysis of covariance (ANCOVA) adjusted for baseline FEV1 and the pooled investigational center.", "populationDescription": "Intent-to-treat (ITT) population included all randomized participants who took at least 1 dose of the assigned study medication and had at least 1 postdose spirometry measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent change", "timeFrame": "Baseline (Predose at Day 22), 2 hours postdose at Day 22", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received albuterol"}, {"id": "OG001", "title": "Placebo-HFA-BAI", "description": "Participants received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.807", "spread": "0.954"}, {"groupId": "OG001", "value": "8.644", "spread": "1.044"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using an analysis of covariance (ANCOVA) with baseline FEV1 as covariate and fixed effects of pooled center and treatment group.", "nonInferiorityType": "OTHER", "pValue": "0.0002", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "Difference in adjusted means", "paramValue": "5.163", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.478", "ciUpperLimit": "7.847"}]}, {"type": "SECONDARY", "title": "Baseline-Adjusted Area Under the Percent-Predicted FEV1 Versus Time Curve Over 6 Hours (PPFEV1 AUEC0-6) at Day 22", "description": "Baseline-adjusted PPFEV1 AUEC0-6 on Study Day 22 was determined using both the Day 1 and Day 22 baselines.", "populationDescription": "ITT population included all randomized participants who took at least 1 dose of the assigned study medication and had at least 1 postdose spirometry measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of predicted FEV1*hour", "timeFrame": "Predose (30 and 5 minutes) and 15, 30, 45, 60, 120, 240, and 360 minutes postdose at Day 22", "groups": [{"id": "OG000", "title": "Albuterol-HFA-BAI", "description": "Participants received albuterol"}, {"id": "OG001", "title": "Placebo-HFA-BAI", "description": "Participants received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"title": "PPFEV1 AUEC0-6 on Day 22 Using Day 22 Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.473", "spread": "4.033"}, {"groupId": "OG001", "value": "11.672", "spread": "4.476"}]}]}, {"title": "PPFEV1 AUEC0-6 on Day 22 Using Day 1 Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.182", "spread": "6.036"}, {"groupId": "OG001", "value": "6.767", "spread": "6.572"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 up to Day 22", "description": "Safety population included all randomized participants who received at least 1 dose of their assigned study medication.", "eventGroups": [{"id": "EG000", "title": "Albuterol-HFA-BAI", "description": "Participants received albuterol", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 0, "otherNumAtRisk": 50}, {"id": "EG001", "title": "Placebo-HFA-BAI", "description": "Participants received placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 45, "seriousNumAffected": 0, "seriousNumAtRisk": 45, "otherNumAffected": 0, "otherNumAtRisk": 45}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products R&D, Inc.", "email": "USMedInfo@tevapharm.com", "phone": "888-483-8279"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M19560", "name": "Procaterol", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}